Fusion Ip Share Discussion Threads

[praipus] 13/2/2014 10:32

bamboo2, typical merger arbitrage is to short the bidder and go long the target assuming it all goes through. In my case I already had an IPO holding so I sold it for a modest profit and bought FIP.

The snag with merger arbitrage here is that IPO are doing a rights issue as well and their portfolio is on fire:-)

So I would have been better of staying long IPO too....cant win them all:-)

[praipus] 13/2/2014 10:14

Morning, good idea IMHO. Takeover from IPO to be paid for in IPO shares, slim possibility of white knight and IPO's spun out portfolio entering the hot catergory :-)

[bamboo2] 13/2/2014 10:04

Hi Praipus, in for a few of these this morning.

[the white house] 27/1/2014 09:23

surprise, surprise, we only had to wait 3 days for some newsflow AND the chance to use the word 'disruptive' is taken without hesitation

Can someone explain how 9 months ago there was a 'log jam' of new launches awaiting to come from the 2 new Uni's because of the new tie in, how NONE so far have been announced? Maybe they'll start appearing this week?

[andrbea] 24/1/2014 12:37

so we have to just sit back & wait (till around March 20 I hear, if things don't change anymore):

answer from the company today:

I can confirm that Fusion shares will automatically be replaced by IP Group shares at the agreed ratio if the offer proceeds. If a Fusion shareholder holds their shares in certificated form a new certificate will be sent, otherwise their CREST account will automatically adjust to IP Group shares.

[praipus] 23/1/2014 11:33

Thought I heard someone with an American accent and a NASDAQ listing application form discussing 105p :-)

FIP 20% accept. FIP get out if another offer comes along in excess of 110% of the current offer and IPO would have seven days to counter bid.
Offer RNS

[the white house] 23/1/2014 07:51

and there's the reason why!

but why?

good of them to quote/use the current price (see previous post) rather than an average of the last 3 months as often happens

with the Diurnal/Chronocort phase 2 results out before the end of this q, which will be worth more than the total value of FIP alone if approved, in 3 or 6 months time, with some of the others motoring as well, this could look a bargain for IP

do i hear 100p at the back?

[the white house] 17/1/2014 19:12

come on guys, two extra Uni's 9 months ago, new appointments made and we're getting less news than ever...should be an update every fortnight not every 12 weeks, pull your fingers out or give us back the 20 mil!?

[the white house] 27/11/2013 20:38

Cheers Dave, great mag the IC!

[davethechef] 27/11/2013 09:52

Keeping on my watch-list after being tipped by the IC last Friday, in their '10-bagger' potential, article; along with about half a dozen candidates.

[the white house] 26/11/2013 10:33

to possibly answer my own question Asalus have been presenting their disruptive Ultravision medical device at one of the Worlds largest medical conferences in Hamburg over 4 days last weekend.

[the white house] 25/11/2013 12:18

a dozen buys Friday and half a dozen today, i'm almost giddy with excitement...presume its something to do with this Graphene IP stuff, anyone help!?

[the white house] 15/10/2013 16:04

Calm before the storm in 2014Diurnal in 1st Q likely to be a disruptive game changer

[ceohunter] 03/9/2013 08:32

video interview

Fusion IP expects a greater number of companies to join its portfolio every year

University commercialisation company Fusion IP's CEO David Baynes told Proactive Investors that he hopes that over the course of the next year they will probably be three to four new companies joining Fusion's portfolio.

[hashertu] 02/9/2013 12:09

Abstract from Chinese magazine shown on the Seren website.
Dated 2 August. Seems the Seren is still alive (and kicking?)

Dr Tong Zhang discusses Seren's latest technologies, patent protection and commercialisation routes with China Solid-state Lighting Alliance.
hxxp://www.china-led.net/info/20130802/1211.shtml - (Chinese language only)

"China 's semiconductor lighting network : development of LED industry in the current situation, Salem photoelectric development plan for the next 3-5 years is what ?

Zhang Tong : the next 5-10 years LED market will be like the PC industry , especially in the last turn of the century the situation of about 10 years , like the bloody price war is inevitable . Through continuous upgrading of technology to achieve low cost conditions attached to enhance light efficiency is the LED enterprise survival and development , occupying a leading position to win. So, if this Salem photoelectric technology development company will have a huge space for development. We expect that within a year fine nano- pillar method will be taken into a domestic enterprise's production lines to produce high quality LED epitaxial wafers and integrated midstream operations. While gradually expanding its influence at home and abroad , penetration and market share. And then for non / semi- polarized composite substrate introduction will further significantly enhance the company 's product quality and core competitiveness, so that it is not only in the brutal competition to survive , and in 3-5 years after the annual output value by in at least 15-20% of the rate of steady growth."

[the white house] 30/8/2013 13:19

2 (two) whole page write up in the current 'Shares' magazine pushing things along. Highlights the potential of Seren, Magnomatics & phasefocus with Diurnal the current darling given its potential £100m? Valuation if the current phase 2 trials are successful. Other Uni's want to get involved & there is still no news about the latest two...however news flow imminent to alleviate any future further cash call

[the white house] 26/6/2013 11:57

MedaPhor really seem to pushing on well with a product with unstoppable worldwide demand. Good update with actual sales data info, company prospects looking stronger all the time

[andrbea] 24/5/2013 13:41

some funds then for investee company, Absynth Biologics


ABINGDON, England, May 3, 2013 /PRNewswire/ --
OBN, the trade association supporting and bringing together the UK's emerging life sciences companies, their corporate partners and investors, has welcomed the allocation thus far of £63m in funding awards to UK life science companies under the Biomedical Catalyst (BMC) scheme administered by the Technology Strategy Board (TSB), during its first 12 months of operation. OBN now calls for the BMC's extension at the same level of investment for a minimum duration of the remainder of the UK Life Sciences Strategy, which began late in 2011 and which the Government announced in the Autumn, would have a 10-year duration.

OBN Member Companies who have thus far been winners of BioMedical Catalyst funding include PsiOxus Therapeutics, Absynth Biologics, KalVista Pharmaceuticals, PhotoBiotics, Oxford BioTherapeutics, Integrated Magnetic Systems, F-Star Biotechnology, Glide Pharma, Prosonix, mapmyhealth, Arecor, Pharminox, Domainex, Summit Corporation, GeneFirst, Pharmidex, Team Consulting and Gentronix.

[the white house] 23/5/2013 15:39

Key day, two ticks up on no trades....newsflow about to recommence!

[andrbea] 20/5/2013 18:53

I like their 52% holding in this company, as the ineffectiveness of antibiotics is a big headache going forward, worldwide


About Us

Novel vaccines and immunologicals – Beating the super bug

Absynth Biologics has been created with the initial goal of developing immunological prophylaxis and therapy to combat bacterial infections. Absynth's strategy is to exploit the characterisation of carefully selected novel proteins Staphylococcus aureus (S. aureus)in bacteria as immunological targets.

These novel targets are being developed as prospective vaccine components and for the production of prophylactic or therapeutic monoclonal antibodies (MAbs). The most advanced programmes target Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).

The market for an MRSA vaccine or therapy is large and growing in the UK and US; hospital acquired infections are an increasing public health concern and are responsible for a rise in the number of hospital deaths.

[the white house] 24/4/2013 20:14

RNS shows Sheffield & Cardiff uni's percentage holding falling, even though the the amount of shares they hold is UNCHANGED as they have always stuck to original investment amount, and some think there's a sell off when if fact no,one has & indeed £20m extra has gone in....

by his interview their sounds like a backlog build of of new formed companies t come, should be a big few months

[lucky_punter] 17/4/2013 14:43

Fusion IP (LON:FIP),

the firm that commercialises hi-tech ideas spun out of Britain's universities, has just released interim figures, but they already feel like yesterday's news.
The report covers the six months until the end of January, but since then Fusion has moved on, having raised £20mln in new funds and begun new partnerships with Nottingham and Swansea universities.

[ipoman2] 16/4/2013 12:29

Earnings today really don't matter.. look what the company has done since: £20mln in the bank, two more universities and a plan:

[tradervic] 15/4/2013 14:39

David Baynes appearing again at a Shares event.


David Baynes, Chief Executive Officer of Fusion IP (FIP) (FIP.L) [LON:FIP] the university IP commercialisation company, will be presenting at the Shares Magazine Innovation & Growth Investor Evening in London on 9th May 2013. The Innovation & Growth Investor Evening will showcase up to 4 leading innovative and imaginative growth companies bringing them together in one room for one evening only! The event offers a unique opportunity not only to hear about their latest plans but also for investors to put questions to senior management of the companies. Presenting at the event will be Fusion IP (LON:FIP), TyraTech (LON:TYR) and VALIRX (LON:VAL). More details at or